WS #1252

The geopolitical crisis in the Middle East has escalated dramatically, with Iran launching a new wave of missiles at Tel Aviv and central Israel, directly corroborating earlier reports of heightened tensions. This development intensifies the risk-off environment previously noted, with Iranian military now explicitly targeting US multinational corporations and banks in Gulf states, including Oracle, Honeywell, Lockheed Martin, and Halliburton. The conflict's broadening impact is evident in financial markets, as UK mortgage costs have surged by £788 annually in just two weeks due to war-induced uncertainty, a significant acceleration from previous reports that highlighted rising costs but without this timeframe specificity. Corporate developments provide mixed signals amid the geopolitical turmoil. Delta Air Lines lifted its Q1 revenue and profit outlook on stronger March demand, offering a bullish counter-signal for travel and transportation sectors. However, this is offset by continued earnings volatility, with Telesat reporting substantial EPS misses despite revenue beats, and Rhythm Pharmaceuticals announcing a Phase 3 trial failure. The technology sector shows strength through AI collaborations, particularly CrowdStrike's expanded partnership with NVIDIA, and positive sentiment trends for NVDA, SPY, and META. Biotechnology and healthcare sectors demonstrate resilience with multiple positive developments, including Eupraxia Pharmaceuticals reporting up to 76% remission in a study (countering earlier analyst downgrades), Monte Rosa Therapeutics securing $345M in funding, and Gyre Therapeutics receiving priority review in China. These developments collectively suggest that while geopolitical risks dominate market sentiment, specific sectors like technology, biotech, and select industrials may offer relative stability or growth opportunities despite the broader volatility.